Modulation of sialylation by sialyltransferases and sialidases plays essential role in carcinogenesis. There are few reports on sialyltransferase, however, the contribution of cytosolic sialidase (Neu2) remains unexplored in pancreatic ductal adenocarcinoma (PDAC). We observed lower expression of Neu2 in different PDAC cells, patient tissues, and a significant strong association with clinicopathological characteristics. Neu2 overexpression guided drug-resistant MIAPaCa2 and AsPC1 cells toward apoptosis as evidenced by decreased Bcl2/Bax ratio, activation of caspase-3/caspase-6/caspase-8, PARP reduction, reduced CDK2/CDK4/CDK6, and cyclin-B1/cyclin-E with unaffected caspase-9. Neu2-overexpressed cells exhibited higher expression of Fas/CD95-death receptor, FasL, FADD, and Bid cleavage confirming extrinsic pathway-mediated apoptosis. α2,6-linked sialylation of Fas helps cancer cells to survive, which is a substrate for Neu2. Therefore, their removal should enhance Fas-mediated apoptosis. Neu2-overexpressed cells indeed showed increased enzyme activity even on membrane. Interestingly, this membrane-bound Neu2 exhibited enhanced association with Fas causing its desialylation and activation as corroborated by decreased association of Fas with α2,6-sialic acid-binding lectin. Additionally, enhanced cytosolic Neu2 inhibited the expression of several growth factor-mediated signaling molecules involved in PI3K/Akt–mTOR pathway probably through desialylation which in turn also causes Fas activation. Furthermore, Neu2-overexpressed cells exhibited reduced cell migration, invasion with decreased VEGF, VEGFR, and MMP9 levels. To the best of our knowledge, this is the first report of cytosolic Neu2 on membrane, its association with Fas, enhanced desialylation, activation, and Fas-mediated apoptosis. Taken together, our study ascertains a novel concept by which the function of Fas/CD95 could be modulated indicating a critical role of upstream Neu2 as a promising target for inducing apoptosis in pancreatic cancer.
More than 90% of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC), is fatal due to poor diagnosis and prognosis1,2. Because of its rapid progression, invasiveness, and drug resistance, most have metastatic cancers3,4,5,6. The multifaceted biological mechanisms remain mostly unknown.
Abnormal glycosylation and fucosylation are common features in cancers7,8,9,10,11. Hence these alterations play a significant role in modulating differentiation, signaling, adhesion, invasiveness, metastasis, and apoptosis12. Pancreatic cancer cells exhibited higher α2,3- and α2,6-linked sialic acids (SAs) which mainly affects its higher rate of metastasis13,14.
Enhanced SAs depend on the balance of SA-modulatory enzymes sialyltransferases and sialidases15,16,17. Elevated levels of the sialyltransferases are common in cancers including PDAC18,19,20,21,22,23,24,25. Mammalian cells have four sialidases namely lysosomal (Neu1), cytosolic (Neu2), membrane bound (Neu3), and luminal (Neu4) differing in their enzymatic property and substrate specificity. They are important for the balance of sialylation and behave differently during carcinogenesis26,27.
Neu2 expression is either very low or undetectable in normal human tissue with the exception of prostate cancer and myoblast28,29,30. Neu2 is repressed in leukemia, melanoma, and colon adenocarcinoma31,32,33.
Death receptor Fas (CD95) stimulates several signaling cascades for inducing apoptosis. This is commonly disrupted and implicated in tumor cell survival34,35. Both O- and N-linked glycans and α2,6-sialylations of Fas are reported in colon cancer36. The substrate specificity of Neu2 is toward glycoproteins/glycolipids and oligosaccharides. However, the functional significance of Neu2 in Fas-mediated apoptosis has received least attention.
PI3K–Akt pathway is upregulated in many cancers37,38. Due to its constitutive activation, PDAC exhibited high metastatic potential and chemoresistance. Many of the pathway molecules are altered by sialylation39,40. The inhibition of PI3K–Akt pathway sometimes is responsible for the activation of Fas-mediated apoptosis in gastric, colon, and prostate cancer41,42,43. Alterations of sialylation of the PI3K pathway molecules cause inactivation of oncogenes like PI3K/mTOR resulting in regression of cancer. Hence, Neu2 may play an important role in desialylation of such pathway molecules which is not fully understood.
Initially, we observed lower expression of Neu2 in different PDAC cell lines and in patient tissues. Moreover, such reduced Neu2 exhibited a significant strong association with clinicopathological characteristics of these patients (Table 1). Accordingly, we aim to establish the role of this cytosolic sialidase on sialylated Fas in Fas-mediated apoptosis in PDAC cell lines with different mutations (Table 2).
Here, we demonstrated that overexpression of cytosolic Neu2 increased enzyme activity on the membrane. Enhanced membrane-bound Neu2 exhibited an increased association with α2,6-linked SAs on Fas causing its desialylation and activation as corroborated by decreased association of Fas with an SA-binding lectin, Sambucus nigra agglutinin (SNA). Such desialylated Fas guided these cells toward enhanced apoptosis through extrinsic pathway. Additionally, enhanced cytosolic Neu2 desialylated several signaling molecules present in PI3K–Akt/mTOR pathway. All these events accelerated apoptosis by inhibiting this pathway which also causes upregulation of Fas expression and activation. These entire processes diminished the survival of Neu2-transfected drug-resistant PDAC cells through abridged cell migration and invasiveness.
To the best of our knowledge, this is the first information for the presence of Neu2 on the membrane and establishing a link between the function of cytosolic Neu2 for desialylation of membrane-bound Fas. Neu2, therefore, may be a pivotal upstream molecule in regulating apoptosis.
Neu2 is downregulated in human pancreatic cancer tissues
Initially, we compared the status of Neu1/Neu2/Neu3/Neu4 in cancer and normal tissue specimens by immunohistochemistry. Optical density score conferred higher Neu1, Neu3, and Neu4 positivity in the tumor tissues (Fig. 1a, b). In contrast, statistically significant low or undetectable expression of Neu2 was observed in all tissues from 20 patients compared to 20 normal counterparts (Table 1). Interestingly, we observed a strong association of reduced expression of Neu2 with clinicopathological characteristics of these patients. This data suggested that the loss of Neu2 possibly helps higher sialylation status in manifestation of this cancer.
Real-time PCR analysis of sialidases in four representatives PDAC cells namely MIAPaCa2, AsPC1, BxPC3, and PANC1 (Table 2) showed reduced Neu2 expression compared to other three sialidases (Fig. 1c). However, MIAPaCa2 and AsPC1 exhibited lowest Neu2 expression amongst them. Interestingly, they also possess different mutations status. Hence, we have selected these two cells for subsequent study. RT-PCR analysis of all these sialidases also showed similar trend in MIAPaCa2 and AsPC1 (Fig. 1d).
Accordingly, Neu2 was transfected in MIAPaCa2 and AsPC1. Neu2-transfected cells exhibited higher mRNA expression of Neu2 than mock both by real time PCR (Fig. 1e) and RT-PCR (Fig. 1f). Western blot analysis also revealed enhanced level of Neu2 protein (Fig. 1g). However, the expression of Neu1, Neu3, and Neu4 remain unchanged in Neu2-overexpressed MIAPaCa2 (Fig. 1h) and AsPC1 (Fig. 1i).
Sialidase activity in Neu2-transfected cells
We measured the sialidase activity both in cytosolic and membrane fractions of Neu2-transfected cells separately at pH 5.5 toward an artificial substrate MU-NeuAc (Fig. 1j–m). An increased cytosolic enzyme activity was observed in the Neu2-transfected MIAPaCa2 (0.2414 ± 0.0044 µM/h/mg protein) compared to mock-transfected (0.09842 ± 0.00026 µM/h/mg protein) cells (Fig. 1j). Similar trend was found in Neu2-transfected AsPC1 (0.2579 ± 0.019 µM/h/mg protein) compared to mock (0.1048 ± 0.0266 µM/h/mg protein) (Fig. 1l).
We also found increased level of sialidase activity on membrane in Neu2-overexpressed MIAPaCa2 (mock = 0.0340 ± 0.0077 vs. Neu2 = 0.07767 ± 0.0107 µM/h/mg protein) (Fig. 1k). Neu2-transfected AsPC1 also exhibited similar pattern; mock = 0.04372 ± 0.0027 vs. Neu2 = 0.09933 ± 0.0108 µM/h/mg protein (Fig. 1m). Hence it may be concluded that though Neu2 is a cytosolic enzyme, it also exhibited slightly higher sialidase activity in membrane fraction.
Neu2 overexpression inhibits cell proliferation
Next, we checked the growth potential of MIAPaCa2 and AsPC1 due to enhanced Neu2 activity by 3-(4,5 dimethyl thiazol-2yl)-2,5 diphenyltetrazolium bromide (MTT) assay. The Neu2-transfected cells revealed an impaired proliferation capacity after 3 days of culture in the serum-starved condition which was used as apoptotic stimuli compared to mock. Less number of viable Neu2-overexpressed MIAPaCa2 (Fig. 2a) and AsPC1 (Fig. 2c) cells compared to mock were observed in microscope.The percent of cell viability was significantly reduced by 51.35 ± 11.74 and 48.67 ± 0.78 in MIAPaCa2 (Fig. 2b) and AsPC1 (Fig. 2d) respectively by MTT.
Neu2-induced apoptosis is confirmed by annexin V/PI
Since significant cell death was observed in Neu2-transfected cells, we checked the mode of this event after 24 h serum starvation. Neu2 overexpression caused surface phosphatidylserine externalization in MIAPaCa2. AnnexinV positivity was 10.90 ± 0.493 compared to 6.47 ± 0.203 in mock-transfected cells illustrating the features of early apoptosis (Fig. 2e). Neu2-transfected AsPC1 also exhibited higher annexin V positivity.
A substantial number (36.9 ± 1.429) of Neu2-transfected MIAPaCa2 lost membrane integrity and showed late apoptotic bodies as evidenced by both annexin V and PI positivity. AsPC1 also showed a similar trend. Hence it is confirmed that growth inhibition in Neu2-transfected cells was due to apoptosis.
Neu2 overexpression modulates cell cycle-related proteins
To determine whether growth inhibition induced by Neu2 was associated with the regulation of cell cycle-related proteins, we checked the status of these molecules both in mock and Neu2-transfected cells by immunoblotting (Fig. 2f). Neu2 overexpression upregulated Chk1 and Chk2. Activated Chk1 and Chk2 subsequently led to the reduction of the cyclins and cyclin-dependent kinases. We observed that early G1-cell cycle phase regulatory proteins (CDK4 and CDK6) were downregulated after Neu2 overexpression. Late G1-phase regulatory proteins (cyclin E and CDK2) were also reduced. Additionally, cyclin B1 involved in the transition of G2 to the M phase was decreased. Modulation of all these proteins suggested that enhanced Neu2 hinders cell growth by impeding different checkpoints, hence it may be stated that as an enzyme it affects the overall cell cycle phases.
Neu2 induces modulation of anti-apoptotic and pro-apoptotic molecules
We then investigated the probable cause of the observed susceptibility to apoptotic stimuli. We found enhanced mRNA expression of the pro-apoptotic genes (Bax) and effector caspase (caspase 3), but not caspase 9 in Neu2-overexpressed MIAPaCa2 compared to mock-transfected cells after 24 and 48 h (Fig. 3a).
We also observed higher mRNA level expression of Bax and Cas3 in both MIAPaCa2 (Fig. 3b) and AsPC1 (Fig. 3c) by real-time PCR analysis after 48 h. However, the lower genetic expressions of caspase 9 were observed in both the cells.
Western blot analysis also showed higher level of Bax in Neu2-transfected MIAPaCa2 (~6.5 fold) and AsPC1 (~1.5 fold), whereas caspase 9 remained unchanged, which is a hallmark protein for the intrinsic apoptotic pathway (Fig. 3d).
Consistent with these data, Neu2-transfected MIAPaCa2 and AsPC1 exhibited decreased level of anti-apoptotic proteins, Bcl-2 (~15.08 and 2.0 fold) respectively. PARP, a DNA-repairing enzyme also reduced in the Neu2-transfected cells compared to Mock. Overall, the reduction of Bcl-2 and upregulation of Bax supports the notion of involvement of enhanced Neu2 in the apoptosis-regulating pathways in these transfected cells.
Neu2 induces reduced cell proliferation through extrinsic apoptotic pathway
Interestingly, we observed a significant increase of activated caspase 6 and caspase 8 which are hallmark proteins for extrinsic apoptosis pathway in Neu2-overexpressed MIAPaCa2 and AsPC1 (Fig. 3e). The cross-talk between the cell surface-mediated apoptotic signal and the mitochondria is caused by Bid, and hence its activation is very important. We observed cleavage of Bid along with the enhanced level of FADD. Taken together, these results suggest that caspase-8 and FADD activation along with cleaved Bid in Neu2-transfected PDAC may be induced by activation of the death receptor-mediated apoptosis.
Enhanced expression of Fas and FasL in Neu2-transfected cells
Next, we searched for the death receptor mechanism in Neu2-transfected cells. We observed a 1.4 and 1.6-fold upregulation of Fas/CD95 in Neu2-transfected MIAPaCa2 (Fig. 3f) and AsPC1 (Fig. 3g) respectively after 24 h by flow cytometry.
Western blot analysis also suggested a significantly enhanced level of Fas and its ligand (FasL) in the transfected cells (Fig. 3e). Therefore, it may be envisioned that though Neu2 is a cytosolic enzyme still it can stimulate apoptosis by the extrinsic pathway involving membrane-bound Fas.
Neu2 reduces linkage-specific sialylation on cell surface
So far we have demonstrated presence of Neu2 on plasma membrane (Fig. 1k, m); accordingly, we checked whether it can reduce linkage-specific sialylation on the cell surface of Neu2-transfected MIAPaCa2 (Fig. 4a) and AsPC1 (Fig. 4b) by flow cytometry. We have found reduced FITC-SNA binding with Neu2-overexpressed cells compared to mock as indicated by lower MFI value being 467.9 ± 142 vs. 607.8 ± 144.6 in MIAPaCa2 and 228.7 ± 32.68 vs. 346.7 ± 34.48 in AsPC1 respectively. In contrast, no detectable change was found when α2,3-linked SA binding lectin (MALII) was used under similar condition (data not shown). This indicates that Neu2 possibly cleaves more α2,6-linked SA from sialoglycoproteins on the cell surface of MIAPaCa2 and AsPC1 as α2,6-linked SA is reported to be the specific substrate for Neu2.
Plausible association of Neu2 on plasma membrane
As we have observed that Neu2 being a cytosolic enzyme can induce apoptosis by the extrinsic-mediated apoptotic pathway involving Fas, so we monitored whether Neu2 is also present on the membrane. Earlier, we have an indication of slightly higher enzyme activity on the membrane of Neu2-transfected MIAPaCa2 (Fig. 1k) and AsPC1 (Fig. 1m) along with less sialylation (Fig. 4a, b).
Now the membrane fractions of these cells were immunoblotted with an anti-Neu2 antibody. We found that higher expression of Neu2 in the membrane of the Neu2 overexpressed MIAPaCa2 (Fig. 4c) and AsPC1 (Fig. 4d). E-cadherin was used to show the purification of membrane fraction. Hence, it may be stated that Neu2 is available on the membrane by an unknown mechanism.
Neu2 is associated with Fas death receptor
So far we have established the involvement of Fas in mediating apoptosis in Neu2-overexpressed cells through extrinsic pathway. Now, we addressed an obvious question what is the relation between membrane-bound Neu2 and Fas. A co-immunoprecipitation with cell lysate (Fig. 4e) and membrane fractions (Fig. 4f) of Neu2-overexpressed MIAPaCa2 and AsPC1 showed that Neu2 is associated with Fas. Higher expression of membrane-bound Neu2 showed more association with the death receptor suggesting possible enhanced desialylation of Fas.
Neu2 causes desialylation of α2,6-linked SAs on Fas
Fas is known to have α2,6-linked SAs. Therefore, we checked if the Fas is a direct target for desialylation of α2,6-linked SAs by Neu2. A co-immunoprecipitation with cell lysate of Neu2-overexpressed MIAPaCa2 (Fig. 4g) and AsPC1 (Fig. 4h) with anti-Fas antibody and detected by SNA exhibited decreased α2,6-linked SAs on Fas. The band corresponding to Fas was less intense indicating that Neu2 overexpression causes its de-sialylation. This showed that α2,6-linked SAs are also present on Fas in PDAC and further reconfirms that they are the true substrate for Neu2.
Neu2 mediates alterations in the sialoglycoprotein profile
To identify a possible molecular link between Neu2 overexpression and its association with Fas, we examined the status of sialoglycoproteins on membrane and cytosolic proteins of transfected cells using SNA and MALII lectins.
SNA-binding membrane proteins showed significant differences between Neu2-transfected MIAPaCa2 compared to mock-transfected cells (Fig. 5a). The major pattern changes occurred between 20 and 75 kDa proteins which underwent a marked loss of SA indicating these sialoglycoproteins as the possible targets for Neu2. Ponceau S stained blot was used to indicate equal loading. Conversely, the appearance of Neu2 transfection in MIAPaCa2 caused only slight changes in the pattern of α2,3-linked sialoglycoproteins.
Similar changes in the reduction of 20 and 100 kDa sialoglycoproteins profiles were observed in cytosolic proteins of transfected MIAPaCa2 (Fig. 5b). It may be noted that most of the molecules in the PI3K-signaling pathway are between 15 and 100 kDa and they are modulated by their sialylation status. Therefore, enhanced cytosolic Neu2 possibly has a direct role in regulating some signaling pathway by desialylation. Therefore, our observation may provide a possible link between Neu2 activity and alterations of growth factor-mediated signaling due to desialylation by Neu2 overexpression.
Neu2 impairs the activity of several signaling molecules involved in PI3K–Akt/mTOR pathway
PI3K is known to play a key role in Akt–mTOR signaling and help cancer cells to survive. So far we have demonstrated the association of α2,6-linked sialylated Fas with membrane-bound Neu2 and its activation through desialylation (Fig. 4g, h). Additionally, enhanced cytosolic Neu2 may have a direct effect on regulating PI3K pathway probably by modulation of sialylation of several molecules involved in this pathway. Inhibition of PI3K pathway causes upregulation of Fas which had been reported42. However, cross talk between enhanced Neu2, inhibition of the PI3K pathway, and Fas activation has not been explored.
Therefore, we turned our attention to the upstream proteins of this pathway involved in uncontrolled proliferation. We observed a decreased level of PI3K in Neu2-transfected MIAPaCa2 and AsPC1 (Fig. 5c). Neu2 overexpression inhibited PDK1 phosphorylation at Ser241. Thus this sialidase possibly reduces the PDK1-mediated Akt/mTOR signaling. PDK1 partially activates Akt phosphorylation at Thr308, we have also found decreased phosphorylation in Neu2-overexpressed cells.
Furthermore, to check the effect in the intracellular phases of signaling, we evaluated specific phosphorylation level of mTOR complexes and its downstream signaling proteins in Neu2-transfected MIAPaCa2 and AsPC1 (Fig. 5d). They exhibited reduced phosphorylation at Ser2481 indicating mTORC2-specific phosphorylation. We examined the phosphorylation status of AKT at Ser473, which is a selective substrate of mTORC2 for confirming this upstream inhibition of mTORC2 signaling in these Neu2-transfected cells. We observed reduced expression of phospho-AKT at Ser473 (Fig. 5c). This observation strongly suggested that Neu2 overexpression had a significant role in the reduction of mTORC2 activity, which in turn decreased the phosphorylation of its substrate AKT at the Ser473.
We also detected slightly reduced levels of phosphorylation of active mTORC1 at Ser 2448 in Neu2-transfected MIAPaCa2 and AsPC1 (Fig. 5d). As PDK1 pathway regulates mTORC1 activity which consequently controls the downstream signaling molecules, therefore, we studied the phosphorylation of S6K1 and 4E-BP1. We observed reduced phosphorylation of S6K1 at Thr389, 4E-BP1 at Thr37/46, and GSK3β after overexpression of Neu2 in these cells suggesting the involvement of mTORC1 also. Taken together, all these observations suggest that overexpression of Neu2 causes reduction of growth factor-mediated several signaling molecules in the PI3K pathway, as a whole through modulation of sialylation which also could activate Fas. Thus, the activated Fas possibly deregulates the overall pathways for cell proliferation.
Enhanced Neu2 reduces cell migration and invasion through the modulation of VEGF, VEGFR, and MMP9
Next, we checked the role of enhanced Neu2 in metastasis through migration and invasion assays. We observed there was no significant change in cell migration of Neu2-overexpressed MIAPaCa2 (Fig. 6a, b) and AsPC1 (Fig. 6c, d) after 8 h by scratch wound assay (Table 3) compared to mock.
Additionally, we investigated the potential ability for invasiveness of Neu2-overexpressed cells. Mock-transfected MIAPaCa2 and AsPC1 invade Matrigel layer after 24 h (Fig. 6e). However, not much invasion of Neu2-transfected cells was observed. The number of invaded cells per-field in mock was much higher than Neu2-transfected cells (Fig. 6f). Taken together, Neu2-transfected cells possess less invasive property (Table 3).
To further strengthen the reduced inability of Neu2-transfected cells in metastasis and invasion, we have checked the status of a few specific hallmark proteins like vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor proteins (VEGFR), and matrix metalloproteinase 9 (Fig. 6g). All these molecules were decreased compared to mock-transfected cells. Hence, it seems that not only enhanced Neu2 induces apoptosis but it can also have the potential to reduce the metastasis even in drug-resistant MIAPaCa2.
Aberrant sialylation in signaling pathways involved in altering their functions leads to abnormal cellular signaling causing major changes in cellular behavior to induce resistance to apoptosis and invasiveness44. Sialyltransferases and sialidases are two important players in this event. The key achievement of our study is to provide evidence for the enhancement of cytosolic Neu2 on the membrane in the Neu2-overexpressed PDAC cells. We have demonstrated for the first time a close association of membrane-bound Neu2 with sialylated Fas, which plays a major regulatory upstream molecule for the activation of Fas through desialylation. Activated Fas, after desialylation, enhanced several apoptotic molecules through extrinsic apoptotic pathway caused by increased Neu2 on the membrane. Fas activation is also modulated by desialylation of several molecules involved in the PI3K pathway by enhanced cytosolic-Neu2 activity. The effect of all these was reflected in decreased metastasis, invasiveness, and cellular proliferation due to decreased PI3K-pathway activity through modulation of sialylation which helps in upregulation of Fas activation due to enhanced Neu2. Moreover, a significant strong association of lower expression status of Neu2 with clinicopathological characteristics in patient tissues has also been demonstrated.
Several reports suggested that higher sialylation status causes cell motility, adhesion, and metastasis by modulating α2,3 sialyltransferase, ST3GalIII, galactosyl transferases in PDAC25. ST6Gal1 also plays an important role in regulating the invasiveness in a fructose-responsive manner24. This enzyme enhances α2,6-sialylation of Fas which confers protection against Fas-mediated apoptosis and facilitates tumor progression in colon cancer36. We have also shown α2,6-sialylation of Fas in PDAC. To the best of our knowledge, this is the first report on Fas-sialylation in PDAC.
Conformation changes of glycoproteins, recognition of functional molecules especially in relation to cancer progression are usually caused by removal of SAs which was catalyzed by a sialidase26. These observations comprised the preface of our study to evaluate the effects of cytosolic-sialidase Neu2, which is present in very low amount in PDAC cells. The role of Neu2 in differentiation events is an extremely regulated process29. Enhanced Neu2 expression leads leukemic cells towards apoptosis31. However, several tumor cells generally with a high degree of malignancy are lacking this sialidase45.
Due to lack of adequate understanding of the mechanism by which Neu2 regulates tumor cell behavior in pancreatic carcinoma, we aimed to explain the significance of Neu2 downregulation. Accordingly, we overexpressed Neu2 in drug-resistant PDAC cells.
Neu2 overexpression showed apoptosis susceptibility toward apoptotic stimuli such as serum deprivation which significantly reduced the proliferation rate. More importantly, this event pushed Neu2-overexpressed cells toward apoptosis as revealed by an increased number of cells in the late apoptotic stage by affecting important cell cycle regulatory molecules along with increasing the expression of the pro-apoptotic and decreasing the anti-apoptotic proteins. Interestingly, caspase 6 and 8 were activated but not caspase 9 hinting for activation of the extrinsic pathway. Furthermore, we observed higher enzyme activity in the membrane fraction. This outcome gave us first notion that Neu2 probably present in the membrane in transfected cells by an unknown mechanism which desialylated α2,6-linked SAs of cell surface sialoglycoproteins. Interestingly, α2,6-linked SAs are considered to be the main substrate for Neu2 in pancreatic cancer. This was corroborated by the significant differences in sialylation profile of various sialoglycoproteins both in membrane and cytosol between mock and Neu2-transfected cells suggesting desialylation may be the cause of the effects which was activated by Neu2. Changes were more prominent in cleaving α2,6-linked sialoglycoproteins. No appreciable changes in the level of α2,3-linked SAs were observed.
The activation of the Fas-apoptotic pathway by the inhibition of the PI3K/Akt pathway was reported in colon cancer42. It was also found that inhibition of PI3K pathway causes Fas activation in gastric cancer and in prostate cancer41,43. Thus, considerable efforts have been made for understanding the molecular crosstalk between PI3K and Fas-mediated cell death in PDAC cells. All these events have been demonstrated pictorially in Fig. 6h.
Taken together, to the best of our knowledge, this is the first evidence demonstrating cytosolic Neu2 on the membrane which plays as an upstream important molecule for establishing a cross-talk between Neu2, activation of Fas, induction of extrinsic pathway and inhibition of PI3K pathway to induce apoptosis in drug-resistant human pancreatic cancer cells.
Material and methods
2′-(4-Methylumbelliferyl)-α-d-N-acetylneuraminic acid (4-MU-NeuAc), 4-methylumbelliferone (MU) and MTT were from Sigma (St. Louis, USA). Anti-Neu1/Neu3 (Invitrogen)/Neu2 (Abnova, Taiwan)/Neu4 (Pierce), PE-Fas (CD95, BD Bioscience, USA) antibodies and all other antibodies were from Cell Signalling Technology (Danvers, USA). PcDNA3.1-Neu2 was the kind gift from Dr. Eugenio Monti.
The surgical specimens were obtained from pancreatic cancer patients who underwent resection of their tumors from Institute of Postgraduate Medical Education and Research Hospital, Kolkata. The Institutional Human Ethical Committee had approved the study. Consent of the patients or their parents/guardians were taken for the sample needed for this study. All the clinicopathological details of patients included in this study are summarized in Table 1.
For immunohistological staining, pancreatic tumors and adjacentnormal tissues were fixed, embedded in paraffin and microtome-sectioned. To assess the expression of all four sialidases (Neu1/Neu2/Neu3/Neu4), the sections were heated in 0.01 M citrate buffer (pH 6.0) for recovery of antigen and incubated with the respective antibodies. The tissue samples were photographed at ×20 magnification and IHC optical density score was measured by ImageJ software. All 40 samples were used for IHC of Neu2, whereas 10 samples were evaluated for Neu1, Neu3, and Neu4.
MIAPaCa2, AsPC1, BxPC3, and PANC1 were purchased from ATCC (Table 2). MIAPaCa2, AsPC1, and BxPC3 cells were cultured in RPMI-1640 medium, and PANC1 was cultured in IMDM medium supplemented with heat-inactivated FCS [10% (v/v)], l-glutamine (0.002 M), antibiotics, and antimycotics (Medium A). STR profiling of MIAPaCa2 and AsPC1 was done at University of Nebraska Medical Center, USA.
Detection of genetic expression of sialidases
Total RNA from cells was extracted using RNeasy mini kit following the manufacturer’s instruction. First strand cDNA was synthesized by ImPromII-Reverse transcription system according to manufacturer’s protocol.
Semi-quantitative RT-PCR was performed on PTC-100 (MJ Research, GMI Ramsey, MN) using PCR kit with specific primers (Table 4). Expression of GAPDH was used as a housekeeping gene. Real-time PCR was performed using a DyNAmo Flash SYBR Green qPCR Kit. Relative amounts of target mRNA were quantitated using the LightCycler 96 (Roche) software with 18S rRNA as internal control. Neu2 level was also detected by western blot analysis using anti-Neu2 antibody.
Transfection of PcDNA3.1-Neu2 into pancreatic cancer cells
MIAPaCa2 and AsPC1 cells (1 × 106/well) in Medium A at 80% confluence were transfected with Neu2 cDNA inserted into the pcDNA3.1 expression vector by the transfection reagent, lipofectamine-ltx according to the manufacturer’s instructions in a six-well plate. The transfection mixture was removed next day and replaced with fresh medium. Mock transfection was used as the control in all the experiments.
Neu2-transfected cells were cultured for 48 h, resuspended in phosphate-buffered saline (PBS), containing pepstatin A (1.0 μg/ml), aprotinin (10 μg/ml), and leupeptin (10 μg/ml). The cells were lysed by sonication (Qsonica-LLC, XL-2000 series, Newtown, CT, USA) and centrifuged at 800 × g for 10 min. The supernatant was further centrifuged at 1,000,00 × g for 30 min to separate cytosolic and membrane fractions. The sialidase activity in cytosol (50 μg) and membrane (100 μg) was determined by using a fluorimetric assay with 4-MU-Neu5Ac (400 μM) as a substrate. The reaction mixture was incubated at 37 °C for 1 h in sodium acetate buffer (50 mM, pH 5.5). Enzymatic activity was expressed as µM of product per h/mg protein.
Cell viability assay
Mock and Neu2-transfected cells (1 × 104/100 μl) were seeded in 96-well culture plates under serum-depletion conditions for 72 h and subsequently incubated with MTT (100 µg/ml) for 3 h. Formazan crystals were dissolved in DMSO and OD was taken at 550 nm in an ELISA reader (Thermo Scientific, USA). In parallel, the viability of the cells was also monitored by inverted microscopy and the microscopic images were captured after 72 h.
Annexin V–PI positivity
Mock and Neu2-transfected cells (1 × 106) were cultured in absence of serum for 24 h. Cells were suspended in annexin V-binding buffer incubated for 45 min in dark at 25 °C. AnnexinV and PI were added according to the manufacturer’s instruction and incubated for 20 min in dark at 4 °C. Acquisition of annexin V and PI positive cells were analyzed by flow cytometry (FACS) (BD LSRFORTESSA) using BD FACSDiva 8.0 software.
Apoptosis detection assays
Mock and Neu2-transfected cells (1 × 106) to apoptotic stimuli was evaluated by culturing cells under serum-depletion conditions for 48 h. Different types of caspases and pro-apoptotic molecules both in genes and proteins levels were detected by RT-PCR and qRT-PCR, western blotting using specific primers (Table 4), and respective antibodies.
Detection of Fas (CD95)
Neu2 and mock-transfected cells (5 × 105) were washed, resuspended in PBS (100 µl), and incubated with PE-conjugated anti-Fas (CD95) antibody for 30 min in the dark and subsequently acquired by FACS.
Detection of linkage-specific SAs through lectin binding by FACS
Presence of linkage-specific SAs in MIAPaCa2 and AsPC1 cells was explored by using two sialic acid-binding lectins namely SNA and Maackia amurensis agglutinin (MALII). Mock and Neu2-transfected (1 × 105) cells were washed and resuspended in lectin binding buffer (20 mM Tris, 0.5 M NaCl, 2.0 mM MnCl2, 2.0 mM MgCl2, 2.0 mM CaCl2). Cells were incubated separately with FITC-conjugated SNA and MALII for 1 h (5.0 μg/ml at 4 °C), and FITC positivity was acquired by FACS.
For detection of the association of Fas with Neu2, mock and Neu2-transfected PDAC cells were lysed. Total cell lysate protein (200 μg) was incubated with the anti-Fas antibody (1:100) overnight at 4 °C. Immuno-complex was incubated with protein A-Sepharose 4B for 3 h, resolved by SDS-PAGE, and subsequently identified using the anti-Neu2 antibodies. Membrane fraction of mock and Neu2-transfected MIAPaCa2 and AsPC1 cells was similarly processed46. Rabbit IgG was used as a negative control.
Detection of sialoglycoproteins on Fas by co-immunoprecipitation with SNA
To detect the status of α2,6-linked sialic acids on Fas in Neu2-overexpressed MIAPaCa2 and AsPC1, cell lysate was incubated with the anti-Fas antibody (1:100) overnight at 4 °C. Immuno-complex was incubated with protein A-Sepharose 4B for 3 h, resolved by SDS-PAGE, and subsequently detected by using the biotinylated SNA and developed with avidin-HRP. Mock-transfected cells were processed similarly for comparison.
Proteins (100 µg) isolated from the membrane and cytosolic fractions of mock and Neu2-transfected MIAPaCa2 cells were separated on (4–20%) gradient SDS-PAGE and transferred onto a PVDF membrane. α2,6- and α2,3-linked SAs were identified by incubating with biotinylated SNA and MALII separately and subsequently developed with avidin-HRP. Ponceau S stained blot was used to indicate equal loading.
Mock and Neu2-transfected MIAPaCa2 and AsPC1 cells (1 × 106) were cultured to >80% confluency in a six-well plate. Three separate scratch wounds were made and incubated for 24 h. Number of cells that moved into the scratched area was observed, and images were taken by using phase contrast microscopy (EVOS, Life Technologies).
Mock and Neu2-overexpressed MIAPaCa2 and AsPC1 cells (2.5 × 104) were suspended in medium (100 μl) without FBS and added to the upper chamber of the insert (6.5 mm diameter, 8 μm pore size; Becton Dickson). Then, it was placed in a 24-well plate with medium and 10% FBS (900 μl). After 24 h, the invaded cells were fixed with 3.7% formaldehyde and stained with crystal violet solution. Cells on the upper side of the insert were removed by a cotton swab. Three randomly selected fields on the lower side of the insert were photographed, and the migrated cells were counted.
All the data were from three independent experiments and statistical analysis was performed using Graph Pad Prism 5. Two tail Student's t test was used to detect the differences between the groups. Standard error bars represent the standard deviation of the mean (±S.D.) and *p < 0.05 represented the significant differences between the means of the two test groups.
Muders, M. H. et al. Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res. 66, 10264–10268 (2006).
Muders, M. H. et al. Targeting GIPC/Synectin in pancreatic cancer inhibits tumor growth. Clin. Cancer 15, 4095–4103 (2009).
Wang, Z. et al. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 31, 1105–1113 (2011).
Sarkar, S. et al. Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo. Int. J. Cancer 132, 695–706 (2013).
Sarkar, S., Mandal, C., Sangwan, R. & Mandal, C. Coupling G2/M arrest to the Wnt/β-catenin pathway restrains pancreatic adenocarcinoma. Endocr. Relat. Cancer 21, 113–125 (2014).
Mandal, C., Sarkar, S., Chatterjee, U., Schwartz-Albiez, R. & Mandal, C. Disialoganglioside GD3-synthase over expression inhibits survival and angiogenesis of pancreatic cancer cells through cell cycle arrest at S-phase and disruption of integrin-β1-mediated anchorage. Int. J. Biochem. Cell Biol. 53, 162–173 (2014).
Mandal, C., Chatterjee, M. & Sinha, D. Investigation of 9-O-acetylated sialoglycoconjugates in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 110, 801–812 (2000).
Chowdhury, S. & Mandal, C. O-acetylated sialic acids: multifaceted role in childhood acute lymphoblastic leukaemia. Biotechnol. J. 4, 361–374 (2009).
Pal, S. et al. Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia. Int. J. Cancer 111, 270–277 (2004).
Narayanan, S. Sialic acid as a tumor marker. Ann. Clin. Lab. Sci. 24, 376–384 (1994).
Büll, C., Stoel, M. A., den Brok, M. H. & Adema, G. J. Sialic acids sweeten a tumor’s life. Cancer Res. 74, 3199–3204 (2014).
Pearce, O. M. & Läubli, H. Sialic acids in cancer biology and immunity. Glycobiology 26, 111–128 (2016).
Ulloa, F. & Real, F. X. Differential distribution of sialic acid in α2, 3 and α2, 6 linkages in the apical membrane of cultured epithelial cells and tissues. J. Histochem. Cytochem. 49, 501–509 (2001).
Bassagañas, S., Pérez-Garay, M. & Peracaula, R. Cell surface sialic acid modulates extracellular matrix adhesion and migration in pancreatic adenocarcinoma cells. Pancreas 43, 109–117 (2014).
Monti, E. et al. Sialidases in vertebrates. A family of enzymes tailored for several cell functions. Adv. Carbohydr. Chem. Biochem. 64, 403–479 (2010).
Mandal, C. Regulation of O-acetylation of sialic acids by sialate-O-acetyltransferase and sialate-O-acetylesterase activities in childhood acute lymphoblastic leukemia. Glycobiology 22, 70–83 (2012).
Mondal, S., Chandra, S. & Mandal, C. Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leuk. Res. 34, 463–470 (2010).
Mandal, C. et al. High level of sialate-O-acetyltransferase activity in lymphoblasts of childhood acute lymphoblastic leukaemia (ALL): enzyme characterization and correlation with disease status. Glycoconj. J. 26, 57–73 (2009).
Glavey, S. V. et al. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood 124, 1765–1776 (2014).
Harvey, B. E. et al. Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res. 52, 1775–1779 (1992).
Zhao, Y. et al. α2,6-Sialylation mediates hepatocellular carcinoma growth in vitro and in vivo by targeting the Wnt/β-catenin pathway. Oncogenesis 6, e343 (2017).
Cao, Y., Merling, A., Crocker, P. R., Keller, R. & Schwartz-Albiez, R. Differential expression of beta-galactosidealpha2,6 sialyltransferase and sialoglycans in normal and cirrhotic liver and hepatocellular carcinoma. Lab. Invest. 82, 1515–1524 (2002).
Bassagañas, S. et al. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E-cadherin function. PLoS ONE 9, e98595 (2014).
Hsieh, C.-C. et al. Elevation of β-galactoside α2, 6-sialyltransferase 1 in a fructose- responsive manner promotes pancreatic cancer metastasis. Oncotarget 8, 7691–7709 (2016).
Pérez-Garay, M. et al. α2,3-Sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int. J. Biochem. Cell Biol. 45, 1748–1757 (2013).
Miyagi, T. Aberrant expression of sialidase and cancer progression. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 84, 407–418 (2008).
Mandal, C. et al. Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells. Int. J. Cancer 126, 337–349 (2010).
Koseki, K. et al. Human cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival. Biochem. Biophys. Res. Commun. 428, 142–149 (2012).
Fanzani, A., Colombo, F., Giuliani, R., Preti, A. & Marchesini, S. Cytosolic sialidase Neu2 upregulation during PC12 cells differentiation. FEBS Lett. 566, 178–182 (2004).
Fanzani, A. et al. Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 cells. FEBS Lett. 547, 183–188 (2003).
Tringali, C. et al. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J. Biol. Chem. 282, 14364–14372 (2007).
Tokuyama, S. et al. Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA. Int. J. Cancer 73, 410–415 (1997).
Sawada, M. et al. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int. J. Cancer 97, 180–185 (2002).
Von Reyher, U. et al. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 58, 526–534 (1998).
Keane, M. M. et al. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56, 4791–4798 (1996).
Swindall, A. F. & Bellis, S. L. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J. Biol. Chem. 286, 22982–22990 (2011).
Sadeghi, N. & GerberD., E. Targeting the PI3K pathway for cancer therapy. Future Med. Chem. 4, 1153–1169 (2012).
Morgensztern, D. & McLeod, H. L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803 (2005).
Zhao, Y. et al. Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. Mol. Cell. Proteom. 13, 520–536 (2014).
Ma, H. et al. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34, 1–15 (2014).
Osaki, M. et al. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J. Cancer Res. Clin. Oncol. 130, 8–14 (2004).
Zhu, L. et al. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. Cancer Lett. 354, 355–364 (2014).
Bertram, J. et al. Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res. 66, 4781–4788 (2006).
Häuselmann, I. & Borsig, L. Altered tumor-cell glycosylation promotes metastasis. Front. Oncol. 4, 28 (2014).
Miyagi, T., Takahashi, K., Hata, K., Shiozaki, K. & Yamaguchi, K. Sialidase significance for cancer progression. Glycoconj. J. 29, 567–577 (2012).
Bhattacharya, K., Maiti, S. & Mandal, C. PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor. Oncogenesis 5, e227 (2016).
S.N. is an SRF of University grant commission (UGC). We sincerely acknowledge Eugenio Monti, Department of Molecular and Translational Medicine, University of Brescia, Italy for providing PcDNA3.1-Neu2 plasmid, Dr. Kaustubh Dutta, Department of Biochemistry and Molecular biology, University of Nebraska Medical Center, USA for STR profiling, Mr. Asish Mallick and Rita Maity for their technical help, Samarpan Maiti and Chandan Mandal for fruitful discussion. Director (CSIR-IICB) is kindly acknowledged for providing all institutional facilities. This study is supported by CSIR (ESC0103), Department of Biotechnology (DBT, GAP 346), Department of Science and Technology (DST, GAP 336/GAP 339), Govt. of India. CM is grateful for financial support by Sir J.C. Bose National Fellowship, DST, Govt. of India and DBT-Distinguished Biotechnology Research professorship award.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nath, S., Mandal, C., Chatterjee, U. et al. Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells. Cell Death Dis 9, 210 (2018). https://doi.org/10.1038/s41419-017-0191-4
This article is cited by
Nature Communications (2023)
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting
Experimental Hematology & Oncology (2022)
CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells
Molecular Cancer (2022)
Transcriptomic networks of gba3 governing specification of the dopaminergic neurons in zebrafish embryos
Genes & Genomics (2022)
Desialylation of Atg5 by sialidase (Neu2) enhances autophagosome formation to induce anchorage-dependent cell death in ovarian cancer cells
Cell Death Discovery (2021)